Introduction
Exertional fatigue and dyspnoea are the dominant symptoms of chronic heart failure although the precise pathophysiology of these symptoms remains undetermined [1] . Certainly, the exercise capability of patients with chronic heart failure bears little relationship to the magnitude of the central haemodynamic disturbance [2] . Abnormalities of skeletal muscle in chronic heart failure are well described and there is increasing evidence that these may be an important determinant of symptoms in chronic heart failure [3] [4] [5] [6] [7] . The histology and biochemistry of skeletal muscle in chronic heart failure is abnormal at rest and on exercise magnetic resonance scanning indicates there is an early onset of anaerobic metabolism with a rapid fall in intracellular pH and a swift depletion of high energy phosphate bonds as determined by a fall in the ratio of phosphocreatine to inorganic phosphate [3] [4] [5] [6] . Phosphocreatine and creatine have integral roles in energy metabolism in skeletal muscle via their part in the creatine kinase equilibrium reaction linked with adenosine triphosphate (ATP) and adenosine diphosphate (ADP) homeostasis (ADP+phosphocreatine ⇔ATP+creatine) [8] . Phosphocreatine may act as a temporal buffer to maintain ATP concentrations at the myofibril via rephosphorylation of ADP [8] . Evidence also exists for a spatial buffering effect of phosphocreatine with phosphocreatine generated at the mitochondria via the creatine kinase reaction diffusing to the myofibril to buffer ADP [9] . The role of phosphocreatine is to deliver high-energy phosphate to the myofibril and to act as a store of high-energy phosphate to regenerate ATP via the creatine kinase reaction during intense muscular contraction. At rest, phosphocreatine is then regenerated via the creatine kinase reaction.
In addition to the exercising abnormalities of phosphocreatine/creatine, resting muscle biopsies in chronic heart failure have demonstrated a reduction in skeletal muscle creatine content and magnetic resonance studies have demonstrated a delay in the resynthesis of phosphocreatine post-exercise [10, 11] .
Creatine is ingested in a normal diet and is found in meat and fish [12] . Dietary supplementation with supraphysiological amounts of creatine in normal volunteers increases skeletal muscle creatine content, increases muscle work and delays the onset of fatigue during exercise and may augment the resynthesis of phosphocreatine after exercise [13] [14] [15] . Creatine supplementation also attenuates the accumulation of humoral markers of metabolic stress during exercise [13, 16] . One study has suggested that creatine supplementation in chronic heart failure produces an increase in skeletal muscle total creatine and phosphocreatine with an improvement in skeletal muscle performance [17] . We have previously shown resting and exercising abnormalities of skeletal muscle metabolism and their relationship to symptoms in chronic heart failure using a forearm model of muscle metabolism [18] . The purpose of this study was to investigate the effects of dietary creatine supplementation on the metabolic response of the forearm to exercise in patients with chronic heart failure.
Methods

Patients
We recruited 20 male patients (mean (SEM) 63·5 (1·4) years) from outpatient clinics. All had stable chronic heart failure of at least 3 months duration. The patient demography is detailed in Table 1 . There were no significant differences in baseline demographic variables between creatine and placebo treated groups. All patients had radiographic cardiomegaly and echocardiographic confirmation of left ventricular dilatation and dysfunction (left ventricular end-diastolic dimension >5·5 cm, fractional shortening <25%). Local ethical approval was obtained and all patients gave written informed consent.
Methods
Patients were studied in an identical manner on two separate days. On the first study day, patients were admitted to a temperature-controlled laboratory (25 C) following an overnight fast and having omitted their usual morning medication. They lay supine on a couch and a 21 gauge endhole cannula was inserted retrogradely into an antecubital vein of the dominant arm. The cannula was advanced distally in the vein in an attempt to sample blood as directly as possible from the forearm muscle bed without contamination from blood draining the skin. Another cannula was inserted, again retrogradely, into a vein on the dorsum of the nondominant hand. This hand was then positioned in a heated 'box' at 55-60 C to arterilize the blood (oxygen saturation 90-95%). The patients then rested supine for 30 min.
After the rest period, venous blood was sampled for measurement of lactate and ammonia and paired samples of venous and arterialized blood for gas analysis (Ciba Corning 238 pH/Blood gas analyser). Ammonia is formed during muscular contraction by the deamination of adenosine monophosphate and the production of ammonia is triggered by the depletion of ATP stores; it is thus a sensitive marker of ATP loss [19] . The patients then exercised the dominant forearm using a hand grip dynanometer. Maximal voluntary contraction was measured from an average of three attempts. After a further 15 min rest, the patients performed isometric contraction, 5 s of sustained contraction followed by 5 s relaxation for 5 min (a total of 30 contractions) at 25%, 50% and 75% of maximal voluntary contraction and then continued at 75% until exhaustion. Each exercise bout was separated by a 5 min rest period. Immediately after each period of exercise, and a further 2 min following the end of each exercise period, blood samples were obtained in an identical way to the resting samples. The patients then rested for a further 30 min and the procedure was repeated but next the patients exercised at fixed workloads of 7, 14 and 21 kg. Patients who completed 30 contractions at the 21 kg workload did not continue exercise to exhaustion. All contractions and rest periods were timed using a stop watch.
Creatine administration
Patients were then randomly allocated in a double-blind design to receive creatine 5 g four times a day or matching placebo for 5 days. On the 6th day patients were restudied in an identical manner to the baseline study. 
Biochemical analysis Lactate
Blood lactate was determined from 1 ml samples of blood which were immediately deproteinized in 3 ml of 10% cold perchloric acid and centrifuged. The supernatant was stored at 20 C until later analysis [20] . The intra-assay coefficient of variation for lactate in our laboratory is 1·0% (n=10) and the inter-assay coefficient of variation for lactate is 3·5% (n=10).
Ammonia
Three ml samples of blood were mixed with lithium heparin and centrifuged, the serum was stored at 80 C until analysis within 36 h of the sampling [21] . The intra-assay coefficient of variation for ammonia in our laboratory is 2·5% (n=10) and the inter-assay coefficent of variation for ammonia is 2·9% (n=10).
Oxygen extraction
Skeletal muscle oxygen extraction was calculated as the ratio of arteriovenous oxygen difference and arterial oxygen content, multiplied by 100%. Arterial oxygen content is calculated as haemoglobin concentration/ dl 1·34 % arterial oxygen saturation.
Statistics
The overall response to exercise for each metabolite and for oxygen extraction before and after creatine and placebo was assessed using the area under the curve method. The effect of creatine and placebo on the number of contractions performed until exhaustion at 75% of maximum voluntary contraction workload was assessed using Wilcoxon's signed rank test. The data are displayed as median and 25th and 75th interquartile range. A P value <0·05 was considered significant.
Results
There were no adverse effects reported after creatine or placebo ingestion and all patients completed the 5 day course of treatment.
Muscle endurance
There was a significant increase after creatine ingestion in the number of contractions performed before exhaustion at the 75% maximum voluntary contraction workload (8 (6, 14) vs 14 (8, 17) , P=0·025) (Fig. 1) . Eight of 10 creatine treated patients demonstrated an improvement. No significant effect was found in placebo-treated patients (12 (6, 21) vs 13·5 (8·5, 20) , P=0·44). There was no effect of creatine or placebo on the number of contractions performed at the 21 kg workload in the fixed protocol, although 9/10 patients in each treatment group completed the protocol before and after randomization.
Metabolic response
There was no significant change in the overall lactate or ammonia response to exercise as assessed by area under the curve after creatine or placebo ingestion at either the 
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%maximum voluntary contraction workload protocol or the fixed workload protocol. However, there was a significant fall in ammonia production after creatine ingestion at the 75% maximum voluntary contraction (volitional exhaustion) workload with the results expressed as ammonia per contraction (11·6 mol/l/ contraction (8·3, 15·7) vs 8·9 mol/l/contraction (5·9, 10·8), P=0·037) (Fig. 2) . There was a similar fall in lactate per contraction at the 75% MVC workload which approached statistical significance (0·32 mmol/l/ contraction (0·28, 0·61) vs 0·27 mmol/l/contraction (0·19, 0·49), P=0·07) (Fig. 3) . Placebo had no significant effect on either lactate (0·3 mmol/l/contraction (0·11, 0·40) vs 0·31 mmol/l/contraction (0·16, 0·40, P=0·399) or ammonia per contraction (6·5 mol/l/contraction (4·5, 8·3) vs 4·9 mol/l/contraction (4·4, 14·7), P=0·221) at the 75% maximum voluntary contraction workload.
Oxygen extraction
There was no significant effect of either creatine or placebo on oxygen extraction (Table 2) .
Discussion
We have shown that dietary creatine supplementation in patients with chronic heart failure produces an improvement in skeletal muscle endurance and an attenuation of the derangement of the metabolic response to exercise observed in chronic heart failure. Previous studies have demonstrated a reduction in total creatine content in skeletal muscle in patients with severe chronic heart failure and that dietary creatine supplementation in chronic heart failure produces a significant increase in skeletal muscle creatine and phosphocreatine content [10, 17] . The mechanism of the favourable changes in the present study is therefore likely to be an increase in forearm skeletal muscle creatine and phosphocreatine content and a consequent maintenance of the cellular ATP to ADP ratio during intense muscular contraction. This may have been achieved as a result of an increase in pre-exercise skeletal muscle phosphocreatine and creatine content, and/or an enhanced resynthesis of phosphocreatine between exercise bouts [14] .
The finding that dietary creatine supplementation in chronic heart failure appeared only to have a significant metabolic effect at workloads close to volitional exhaustion should not be surprising. During submaximal exercise there is little dependence on phosphocreatine availability and intracellular levels of ATP are maintained. The availability of phosphocreatine is one of the most important limitations to muscle performance during intense, fatiguing muscular contractions [22, 23] . Therefore it is not unexpected that during the relatively low intensity fixed workload protocol and at workloads of 50% maximum voluntary contraction or less where subjects are working submaximally that dietary creatine supplementation had no effect.
The improvements in skeletal muscle endurance and the metabolic response to exercise after creatine supplementation in chronic heart failure we have described are relatively small and it is uncertain whether they would result in a meaningful improvement in symptoms or conventional treadmill exercise tolerance. However, relatively small increases in skeletal muscle metabolites at rest and on exercise in chronic heart failure are associated with important changes in symptomatic status [18] . It is possible that a small improvement in abnormalities of skeletal muscle metabolism may result in substantial symptomatic improvement. There is an increasing body of evidence suggesting a pivotal role for abnormalities of skeletal muscle metabolism in the pathogenesis of symptoms in chronic heart failure and any intervention which can favourably affect these mechanisms is potentially important [7, 18, 24] . However, it is arguable if the majority of patients with chronic heart failure in their customary activity ever exercise to a truly maximal level where creatine supplementation is most likely to be effective [25] . We may have underestimated the possible metabolic effects of creatine supplementation in chronic heart failure. In normal volunteers, there is a large interindividual variation in skeletal muscle creatine uptake after creatine supplementation, and it is probable that some of our creatine treated patients did not increase their skeletal muscle creatine content [15] . Recent work suggests that the uptake of creatine into the skeletal muscle of normal subjects is enhanced by concomitant carbohydrate loading [26] . The improvement in skeletal muscle endurance after creatine loading in normal volunteers correlates with the increase in skeletal muscle creatine and the effects seen in the present study may be augmented by concomitant carbohydrate loading. We have also studied a relatively small muscle bulk in the forearm. We chose to study the forearm as this enables blood sampling as close as possible to the muscle bed, avoiding dilution from metabolically inactive tissue. Previous studies involving creatine supplementation have involved the large muscle groups of the leg and a more marked response to creatine may have been produced in a larger muscle.
We have demonstrated an improvement in the metabolic response and endurance of skeletal muscle in chronic heart failure as determined within 12 h of the completion of dietary creatine supplementation. We have not determined the duration of these favourable effects. However, the observation that in normal volunteers muscle creatine remains elevated for several weeks after dietary creatine supplementation with 20 g daily for 5 days demonstrates that creatine is 'trapped' within skeletal muscle once absorbed and would suggest that the favourable effect of creatine may be relatively long-lived [27, 28] . The most important limitation to the present study was the use of volitional exercise rather than electrical stimulation of skeletal muscle. We studied a group of severely symptomatic patients and chose to use volitional exercise to avoid the significant discomfort associated with electrical stimulation. Although subjects exercised only to volitional exhaustion they were given verbal encouragement to ensure optimum performance. The design of the study was double-blind and so no patient or physician bias could be introduced.
We have demonstrated that dietary creatine supplementation in chronic heart failure produces favourable effects on skeletal muscle endurance and metabolism. The potential for dietary creatine supplementation in chronic heart failure to produce significant longer term improvements in symptoms and exercise performance requires further study. 
